FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

GSK Submits Additional Zofran Study Info to FDA

[ Price : $8.95]

GlaxoSmithKline submits to FDA additional materials involving an assessment of its Zofran.

Fresenius Kabi BLA for Neulasta Biosimilar

[ Price : $8.95]

FDA accepts for review a Fresenius Kabi BLA for a pegfilgrastim biosimilar candidate (MSB11455) that references Amgens Neulasta.

FDA Denies Vagus Nerve Stimulation Petition

[ Price : $8.95]

FDA denies a Public Citizen petition asking it to revoke the PMA approval for Cyberonics Vagus Nerve Stimulation device for use in...

PMA, HDE Supplement Covid-19 Guidance

[ Price : $8.95]

FDA says it will not object to some design or manufacturing modifications for devices approved through a PMA or HDE during the Cov...

Latest FDA Warning Letters

[ Price : $8.95]

FDA releases its latest batch of Warning Letters that includes Altaire Pharmaceuticals and Samchundang Pharm.

FDA Clears Smart Medical G-Eye Colonoscope

[ Price : $8.95]

FDA clears a Smart Medical Systems 510(k) for the G-Eye Colonoscope.

ICH Guidelines for Exposure to 3 Solvents

[ Price : $8.95]

FDA releases a draft ICU guideline of permitted daily exposure to three solvents.

Repeated CGMP Violations at Altaire

[ Price : $8.95]

FDA warns Altaire Pharmaceuticals about repeat CGMP violations in its manufacturing of finished drugs.

User Fee Financial Details Virtual Meeting

[ Price : $8.95]

Federal Register notice: FDA announces a 6/22 virtual public meeting entitled Financial Transparency and Efficiency of the Prescri...

3 CGMP Violations at Koreas Samchundang Pharm

[ Price : $8.95]

FDA warns South Koreas Samchundang Pharm about CGMP violations in its manufacturing of finished drugs.